A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute suggests that an unusual experimental drug, called AS1411, can reduce breast-cancer aggressiveness, reverse resistance to the drug fulvestrant and perhaps improve the effectiveness of other breast-cancer drugs. Read more here.
Study mentioned: Pichiorri F, et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med. 2013 Apr 22. [Epub ahead of print] PMID: 23610125
No comments:
Post a Comment